AUC curve for lncRNA NKILA, NEAT1, MALAT1, MIAT with respect to patients with T2DM with nephropathy versus patients without nephropathy and patients with T2DM with retinopathy versus without retinopathy
| Gene | AUC | Cut-off | Sensitivity | Specificity | P value |
| Patients with T2DM with nephropathy versus without nephropathy | |||||
| NKILA | 0.48 | 3.0 fold | 54% | 40% | 0.63 |
| NEAT1 | 0.52 | 4.5 fold | 52% | 48% | 0.37 |
| MALAT1 | 0.48 | 4.2 fold | 53% | 40% | 0.65 |
| MIAT | 0.53 | 3.2 fold | 55% | 50% | 0.40 |
| Patients with T2DM with nephropathy versus without nephropathy | |||||
| NKILA | 0.56 | 3.1 fold | 59% | 41% | 0.12 |
| NEAT1 | 0.57 | 4.6 fold | 61% | 51% | 0.09 |
| MALAT1 | 0.60 | 4.3 fold | 61% | 50% | 0.01 |
| MIAT | 0.66 | 3.5 fold | 68% | 58% | <0.0001 |
AUC, type 2 diabetes mellitus; lncRNA, long non-coding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MIAT, myocardial infarction-associated transcript; NEAT1, nuclear enriched abundant transcript 1; NKILA, NF-kappaB interacting lncRNA; T2DM, type 2 diabetes mellitus.